Literature DB >> 21993424

Blinding in randomized clinical trials: imposed impartiality.

A Hróbjartsson1, I Boutron.   

Abstract

Blinding, or "masking," is a crucial method for reducing bias in randomized clinical trials. In this paper, we review important methodological aspects of blinding, emphasizing terminology, reporting, bias mechanisms, empirical evidence, and the risk of unblinding. Theoretical considerations and empirical analyses support the blinding of patients, health-care providers, and outcome assessors as to the trial intervention to which patients have been allocated. We encourage extensive pretrial testing of blinding procedures and explicit reporting of who was in the blinded condition and the methods used to ensure blinding.

Entities:  

Mesh:

Year:  2011        PMID: 21993424     DOI: 10.1038/clpt.2011.207

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Authors:  An-Wen Chan; Jennifer M Tetzlaff; Peter C Gøtzsche; Douglas G Altman; Howard Mann; Jesse A Berlin; Kay Dickersin; Asbjørn Hróbjartsson; Kenneth F Schulz; Wendy R Parulekar; Karmela Krleza-Jeric; Andreas Laupacis; David Moher
Journal:  BMJ       Date:  2013-01-08

Review 2.  The placebo response in medicine: minimize, maximize or personalize?

Authors:  Paul Enck; Ulrike Bingel; Manfred Schedlowski; Winfried Rief
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

3.  I am not biased. It is everyone else's problem.

Authors:  Tim R Watkins; Lisa A Harvey
Journal:  Spinal Cord       Date:  2020-04-07       Impact factor: 2.772

4.  Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto.

Authors:  Jeannette Y Lee; Page Moore; John Kusek; Michael Barry
Journal:  J Altern Complement Med       Date:  2013-02-05       Impact factor: 2.579

Review 5.  Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies.

Authors:  Asbjørn Hróbjartsson; Frida Emanuelsson; Ann Sofia Skou Thomsen; Jørgen Hilden; Stig Brorson
Journal:  Int J Epidemiol       Date:  2014-05-30       Impact factor: 7.196

6.  Impact of Blinding on Patient-Reported Outcome Differences Between Treatment Arms in Cancer Randomized Controlled Trials.

Authors:  Fabio Efficace; David Cella; Neil K Aaronson; Melanie Calvert; Francesco Cottone; Massimo Di Maio; Francesco Perrone; Francesco Sparano; Eva-Maria Gamper; Marco Vignetti; Johannes M Giesinger
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

Review 7.  The matching quality of experimental and control interventions in blinded pharmacological randomised clinical trials: a methodological systematic review.

Authors:  Segun Bello; Maoling Wei; Jørgen Hilden; Asbjørn Hróbjartsson
Journal:  BMC Med Res Methodol       Date:  2016-02-13       Impact factor: 4.615

8.  Effectiveness of a Blended Multidisciplinary Intervention for Patients with Moderate Medically Unexplained Physical Symptoms (PARASOL): Protocol for a Cluster Randomized Clinical Trial.

Authors:  Paula Elisabeth van Westrienen; Martijn F Pisters; Suze Aj Toonders; Marloes Gerrits; Cindy Veenhof; Niek J de Wit
Journal:  JMIR Res Protoc       Date:  2018-05-08

9.  Blinding in pharmacological trials: the devil is in the details.

Authors:  Mandy Wan; Mine Orlu-Gul; Helene Legay; Catherine Tuleu
Journal:  Arch Dis Child       Date:  2013-07-29       Impact factor: 3.791

10.  Promoting public access to clinical trial protocols: challenges and recommendations.

Authors:  An-Wen Chan; Asbjørn Hróbjartsson
Journal:  Trials       Date:  2018-02-17       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.